Tigecycline use in critically ill patients: A multicentre prospective observational study in the intensive care setting

Intensive Care Medicine

Volumn 40, Issue 7, 2014, Pages 988-997

  Montravers, Philippe ^a   Dupont, Hervé ^b   Bedos, Jean Pierre ^c   Bret, Philippe ^d  

^a BICHAT HOSPITAL   (France)

^b AMIENS UNIVERSITY HOSPITAL   (France)

^c CENTRE HOSPITALIER DE VERSAILLES   (France)

^d PFIZER INC   (United States)

Author keywords

Intensive care; Multidrug resistance; Organ failure; Severe infections; Tigecycline

Indexed keywords

AMINOGLYCOSIDE; CEPHALOSPORIN DERIVATIVE; PENICILLIN DERIVATIVE; TIGECYCLINE; ANTIINFECTIVE AGENT; MINOCYCLINE;

ABDOMINAL INFECTION; ACUTE KIDNEY FAILURE; ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BLOOD CULTURE; CRITICALLY ILL PATIENT; DISEASE SEVERITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; FEMALE; HOSPITAL INFECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTENSIVE CARE UNIT; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MORGANELLA MORGANII; MULTICENTER STUDY; OBESITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRESCRIPTION; PROSPECTIVE STUDY; PYREXIA IDIOPATHICA; SENSITIVITY AND SPECIFICITY; SEPTIC SHOCK; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SKIN AND SOFT TISSUE INFECTION; SKIN INFECTION; SOFT TISSUE INFECTION; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; CRITICAL ILLNESS; CROSS INFECTION; DRUG COMBINATION; FRANCE; IMMUNOCOMPROMISED PATIENT; INFECTION; MICROBIOLOGY; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; SEVERITY OF ILLNESS INDEX; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BACTEREMIA; CRITICAL ILLNESS; CROSS INFECTION; DRUG THERAPY, COMBINATION; FEMALE; FRANCE; HOSPITAL MORTALITY; HUMANS; IMMUNOCOMPROMISED HOST; INFECTION; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; MINOCYCLINE; MULTIVARIATE ANALYSIS; OBESITY; PATIENT OUTCOME ASSESSMENT; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84903273696     PISSN: 03424642     EISSN: 14321238     Source Type: Journal    
DOI: 10.1007/s00134-014-3323-7     Document Type: Article

References (43)

1. Breedt J, Teras J, Gardovskis J, Maritz FJ, Vaasna T, Ross DP, Gioud-Paquet M, Dartois N, Ellis-Grosse EJ, Loh E et al (2005) Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a doubleblind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 49:4658-4666. doi: 10.1128/AAC.49.11.4658-4666.2005 (Pubitemid 41552597)
2. Ellis-Grosse EJ, Babinchak T, Dartois N, Rose G, Loh E et al (2005) The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 41(Suppl 5):S341-S353. doi: 10.1086/431675 (Pubitemid 41170381)
3. Sacchidanand S, Penn RL, Embil JM, Campos ME, Curcio D, Ellis-Grosse E, Loh E, Rose G (2005) Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial. Int J Infect Dis 9:251-261. doi:10.1016/j.ijid. 2005.05.003
4. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E et al (2005) The efficacy and safety of tigecycline for the treatment of complicated intraabdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 41(Suppl 5):S354-S367. doi: 10.1086/431676 (Pubitemid 41170382)
5. Fomin P, Beuran M, Gradauskas A, Barauskas G, Datsenko A, Dartois N, Ellis-Grosse E, Loh E et al (2005) Tigecycline is efficacious in the treatment of complicated intraabdominal infections. Int J Surg 3:35-47. doi:10.1016/j.ijsu.2005.03.011 (Pubitemid 41095566)
6. Oliva ME, Rekha A, Yellin A, Pasternak J, Campos M, Rose GM, Babinchak T, Ellis-Grosse EJ, Loh E et al (2005) A multicenter trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections [Study ID Numbers: 3074A1-301-WW; ClinicalTrials.gov Identifier: NCT00081744]. BMC Infect Dis 5:88. doi:10.1186/1471-2334-5-88
7. Towfigh S, Pasternak J, Poirier A, Leister H, Babinchak T (2010) A multicentre, open-label, randomized comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalized subjects with complicated intraabdominal infections. Clin Microbiol Infect 16:1274-1281. doi:10.1111/j.1469-0691.2010.03122.x
8. Bergallo C, Jasovich A, Teglia O, Oliva ME, Lentnek A, de Wouters L, Zlocowski JC, Dukart G, Cooper A, Mallick R et al (2009) Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis 63:52-61. doi:10.1016/j.diagmicrobio.2008.09.001
9. Freire AT, Melnyk V, Kim MJ, Datsenko O, Dzyublik O, Glumcher F, Chuang YC, Maroko RT, Dukart G, Cooper CA, Korth-Bradley JM, Dartois N, Gandjini H et al (2010) Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 68:140-151. doi:10.1016/j.diagmicrobio.2010.05.012
10. Tanaseanu C, Bergallo C, Teglia O, Jasovich A, Oliva ME, Dukart G, Dartois N, Cooper CA, Gandjini H, Mallick R et al (2008) Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia. Diagn Microbiol Infect Dis 61:329-338. doi: 10.1016/j.diagmicrobio. 2008.04.009 (Pubitemid 351858575)
11. Florescu I, Beuran M, Dimov R, Razbadauskas A, Bochan M, Fichev G, Dukart G, Babinchak T, Cooper CA, Ellis-Grosse EJ, Dartois N, Gandjini H et al (2008) Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycinresistant enterococci: a phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother 62(Suppl 1):i17-i28. doi: 10.1093/jac/dkn250
12. Vasilev K, Reshedko G, Orasan R, Sanchez M, Teras J, Babinchak T, Dukart G, Cooper A, Dartois N, Gandjini H, Orrico R, Ellis-Grosse E et al (2008) A phase 3, open-label, noncomparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae. J Antimicrob Chemother 62(Suppl 1):i29-i40. doi:10.1093/jac/dkn249
13. Bassetti M, Nicolini L, Repetto E, Righi E, Del Bono V, Viscoli C (2010) Tigecycline use in serious nosocomial infections: a drug use evaluation. BMC Infect Dis 10:287. doi: 10.1186/1471-2334-10-287
14. Curcio D, Fernandez F, Cane A, Barcelona L, Stamboulian D (2008) Indications of a new antibiotic in clinical practice: results of the tigecycline initial use registry. Braz J Infect Dis 12:198-201
15. Swoboda S, Ober M, Hainer C, Lichtenstern C, Seiler C, Wendt C, Hoppe-Tichy T, Buchler M, Weigand MA (2008) Tigecycline for the treatment of patients with severe sepsis or septic shock: a drug use evaluation in a surgical intensive care unit. J Antimicrob Chemother 61:729-733. doi:10.1093/jac/dkm541 (Pubitemid 351321153)
16. Gardiner D, Dukart G, Cooper A, Babinchak T (2010) Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials. Clin Infect Dis 50:229-238. doi: 10.1086/648720
17. Bassetti M, Eckmann C, Bodmann KF, Dupont H, Heizmann WR, Montravers P, Guirao X, Capparella MR, Simoneau D, Sanchez Garcia M (2013) Prescription behaviours for tigecycline in real-life clinical practice from five European observational studies. J Antimicrob Chemother 68(Suppl 2):ii5-ii14. doi:10.1093/jac/dkt140
18. Eckmann C, Montravers P, Bassetti M, Bodmann KF, Heizmann WR, Sanchez Garcia M, Guirao X, Capparella MR, Simoneau D, Dupont H (2013) Efficacy of tigecycline for the treatment of complicated intra-abdominal infections in real-life clinical practice from five European observational studies. J Antimicrob Chemother 68(Suppl 2):ii25-ii35. doi:10.1093/jac/dkt142
19. Montravers P, Bassetti M, Dupont H, Eckmann C, Heizmann WR, Guirao X, Garcia MS, Capparella MR, Simoneau D, Bodmann KF (2013) Efficacy of tigecycline for the treatment of complicated skin and soft-tissue infections in real-life clinical practice from five European observational studies. J Antimicrob Chemother 68(Suppl 2):ii15-ii24. doi:10.1093/jac/dkt141
20. Heizmann WR, Dupont H, Montravers P, Guirao X, Eckmann C, Bassetti M, Garcia MS, Capparella MR, Simoneau D, Bodmann KF (2013) Resistance mechanisms and epidemiology of multiresistant pathogens in Europe and efficacy of tigecycline in observational studies. J Antimicrob Chemother 68(Suppl 2):ii45-ii55. doi:10.1093/jac/dkt144
21. Guirao X, Sanchez Garcia M, Bassetti M, Bodmann KF, Dupont H, Montravers P, Heizmann WR, Capparella MR, Simoneau D, Eckmann C (2013) Safety and tolerability of tigecycline for the treatment of complicated skin and soft-tissue and intra-abdominal infections: an analysis based on five European observational studies. J Antimicrob Chemother 68(Suppl 2):ii37-ii44. doi: 10.1093/jac/dkt143
22. McCabe W, Jackson G (1962) Gramnegative bacteremia: I Etiology and ecology. Arch Intern Med 110:847-855
23. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R (1973) Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60:646-649
24. Le Gall JR, Lemeshow S, Saulnier F (1993) A new simplified acute physiology score (SAPS II) based on a European/North American multicenter study. JAMA 270:2957-2963 (Pubitemid 24000804)
25. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG (1996) The SOFA (sepsis-related organ failure assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22:707-710
26. Jaeschke R, Guyatt G, Sackett DL (1994) Users' guides to the medical literature. III. How to use an article about a diagnostic test. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA 271:389-391
27. Chen Z, Wu J, Zhang Y, Wei J, Leng X, Bi J, Li R, Yan L, Quan Z, Chen X, Yu Y, Wu Z, Liu D, Ma X, Maroko R, Cooper A (2010) Efficacy and safety of tigecycline monotherapy vs. imipenem/ cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial. BMC Infect Dis 10:217. doi: 10.1186/1471-2334-10-217
28. Cai Y, Wang R, Liang B, Bai N, Liu Y (2011) Systematic review and metaanalysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 55:1162-1172. doi: 10.1128/AAC.01402-10
29. Tasina E, Haidich AB, Kokkali S, Arvanitidou M (2011) Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 11:834-844. doi: 10.1016/S1473-3099(11)70177-3
30. Vardakas KZ, Rafailidis PI, Falagas ME (2012) Effectiveness and safety of tigecycline: focus on use for approved indications. Clin Infect Dis 54:1672-1674. doi:10.1093/cid/cis239
31. FDA (2010) http://www.fda.gov/ drugs/drugsafety/ucm224370.htm. Accessed 1 Jan 2014
32. EMA (2011) http://www. ema.europa.eu/docs/en-GB/ document-library/ Medicine-QA/ human/000644/WC500102228.pdf. Accessed 1 Jan 2014
33. EMA (2012) http://www.ema.europa. eu/docs/en-GB/document-library/ EPAR---Summary-for-the-public/ human/000644/WC500044509.pdf. Accessed 1 Jan 2014
34. Prasad P, Sun J, Danner RL, Natanson C (2012) Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 54:1699-1709. doi:10.1093/cid/cis270
35. Yahav D, Lador A, Paul M, Leibovici L (2011) Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 66:1963-1971. doi:10.1093/jac/dkr242
36. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I (2008) Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 36:1089-1096. doi: 10.1097/CCM.0b013e3181691b99 (Pubitemid 351482655)
37. Pletz MW, Lipman J (2013) Clinical measures for increased creatinine clearances and suboptimal antibiotic dosing. Intensive Care Med 39:1322-1324. doi: 10.1007/s00134-013-2918-8
38. Falagas ME, Vardakas KZ, Tsiveriotis KP, Triarides NA, Tansarli GS (2014) Effectiveness and safety of high-dose tigecycline-containing regimens for the treatment of severe bacterial infections. Int J Antimicrob Agents. doi: 10.1016/j.ijantimicag.2014.01.006
39. Paiva JA (2013) Adding risk factors for potentially resistant pathogens, increasing antibiotic pressure and risk creating the "untreatable bacteria": time to change direction. Intensive Care Med 39:779-781. doi: 10.1007/s00134-012-2811-x
40. Pankey GA, Sabath LD (2004) Clinical relevance of bacteriostatic versus bactericidal mechanisms of action in the treatment of Gram-positive bacterial infections. Clin Infect Dis 38:864-870. doi:10.1086/381972 (Pubitemid 38387236)
41. Curcio D, Vargas SW, Ugarte Ubiergo S, Varon F, Rojas Suarez J, Paz Chavez C, Curiale A et al (2011) Tigecycline treatment of critically ill patients: the LatinUser experience. Curr Clin Pharmacol 6:18-25
42. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, Osborn TM, Nunnally ME, Townsend SR, Reinhart K, Kleinpell RM, Angus DC, Deutschman CS, Machado FR, Rubenfeld GD, Webb S, Beale RJ, Vincent JL, Moreno R et al (2013) Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 39:165-228. doi: 10.1007/s00134-012-2769-8
43. Tumbarello M, De Pascale G, Trecarichi EM, Spanu T, Antonicelli F, Maviglia R, Pennisi MA, Bello G, Antonelli M (2013) Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients. Intensive Care Med 39:682-692. doi: 10.1007/s00134-013-2828-9